GlycoNoVi is advancing the understanding of norovirus-glycan interactions through innovative approaches that go beyond the current state of the art. The project has developed a unique library of synthetic and enzymatically produced glycans, enabling high-precision screening for antiviral properties. Cutting-edge structural techniques, including advanced NMR and molecular modeling, have provided intresting insight into glycan binding mechanisms. Additionally, novel covalent inhibitors and multivalent glycan constructs are being explored as potential therapeutic strategies.
A panel of norovirus strains was cloned and recombinant proteins were cloned to generate VLPs, VP1-luciferease and P domains.
Small crystals clusters were obtained for GII.17 P domain, a genotype considered to be an emergent and circulating strain. Co-crystallisation of HMOs and blood group antigens with GII.17 P domain is under optimization.
These findings might greatly contribute to the design of new antiviral approaches, the development of innovative diagnostic tools and to future clinical translation. To maximize the impact of the project, in addition to the network’s industrial partners, regulatory support, and collaborations with actors outside the consortium are taken into account.